Palladio Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Palladio Biosciences, Inc.
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.